Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Moving Average Envelope

Score

-1.1

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 27 18.0 0.30% 0.42% 18.8% -3.4% 84.9%
SHORT 27 9.3 0.15% 0.17% 3.9% -5.8% -123.4%

Summary

Technical Analysis


Moving Average Envelopes are percentage-based envelopes set above and below a moving average. The moving average which forms the base for this indicator can be a simple or exponential moving average. Each envelope is then set the same percentage above or below the moving average. This creates parallel bands that follow price action. With a moving average as the base Moving Average Envelopes can be used as a trend following indicator.

Calculation: Moving Average Envelope:
1) Upper Envelope: 20-day SMA + (20-day SMA x .025);
2) Lower Envelope: 20-day SMA - (20-day SMA x .025);


PROFILE: Ra Pharmaceuticals Inc (RARX)


Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Moving Average Envelope

Download
Company Close Change(%) Volume Value Signal
NVAX Novavax Inc 5.74 20.1 9,559,800 33.27 BULLISH
LSCC Lattice Semicond 23.34 9.7 7,172,000 31.62 BULLISH
IIIN Insteel Industries 26.01 6.9 349,900 27.64 BULLISH
WING Wingstop 93.32 6.5 833,300 17.89 BULLISH
QCOM Qualcomm Inc 95.91 4.5 23,694,300 62.87 BULLISH
ATRC Atricure Inc 38.25 4.1 790,500 6.5 BULLISH
MERC Mercer Intl Inc 13.25 3.7 299,000 10.99 BULLISH
RUN Sunrun Inc 17.18 3.5 3,455,500 4.9 BULLISH
ASNA Ascena Retail 6.5 3.5 328,800 13.69 BULLISH
FOSL Fossil Group 8.32 2.7 965,800 22.27 BULLISH